Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Exclusion Criteria

• •1. Presence of any severe mental illness that could affect interpretation of efficacy data, such as schizophrenia or bipolar affective disorder; any untreated or unstable psychiatric condition including depressive disorder or anxiety disorder.
• •2. History of stroke or other significant neurological disorder
• •3. Transient ischemic attack (TIA) with ongoing cognitive sequelae
• •4. Chronic atrial fibrillation or uncontrolled atrial fibrillation prior to surgery
• •5. Myocardial infarction (MI) within the last 8 weeks and/or previous history of more than 3 MIs
• •6. History of liver dysfunction with ongoing sequelae (including but not limited to liver enzymes \> 2.5 x upper limit or normal (ULN) at screening).
• •7. History of renal dysfunction with ongoing sequelae (including but not limited to creatinine value \> 2.5 mg/dL at screening).
• •8. Known active alcohol or drug abuse.
• •9. Concurrent use of prescription medications known to enhance memory
• •10. General anesthesia (defined as anesthesia requiring intubation or ventilatory support) within 3 months prior to randomization.
• •11. Cardiopulmonary bypass or thoracotomy within 2 years prior to randomization.
• •12. Undergoing valvular repair or replacement during scheduled CABG surgery.
• •13. Chronic obstructive pulmonary disease (COPD) requiring oxygen therapy.
• •14. Decompensating congestive heart disease
• •15. Subjects on immunosuppressive drugs, such as azathioprine, chemotherapeutic agents, mycophenolate, monoclonal antibodies, or more than 20 mg/day prednisone, within the previous 3 months
• •16. Receipt of any investigational agent or device within 30 days of screening.